Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
← catalyst calendarSponsored by United Therapeutics (industry) · UTHR — their whole pipeline →.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
598actual
Sites
98
Countries
Canada, Chile, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-06-01 | actual | When the study began enrolling |
| Primary completion | 2026-02-02 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-02-02 | actual | The whole study's end, after follow-up |
| First posted | 2021-01-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Idiopathic Pulmonary Fibrosis
- Interstitial Lung Disease
Interventions
- Drug: Placebo
- Drug: Inhaled Treprostinil — also filed as Tyvaso
- Device: Treprostinil Ultrasonic Nebulizer
Primary outcome
what the primary-completion date above is the date OFChange in Absolute FVC from Baseline to Week 52
measured Baseline to Week 52
Publications
- PMID 42149993 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · UTHR's whole pipeline · Catalyst calendar · Every registered study · What changed